Skip to main content

Advertisement

SpringerLink
Log in

Advances in Treatment of Diffuse Midline Gliomas

  • Review
  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Diffuse midline gliomas (DMGs) generally carry a poor prognosis, occur during childhood, and involve midline structures of the central nervous system, including the thalamus, pons, and spinal cord.

Recent Findings

To date, irradiation has been shown to be the only beneficial treatment for DMG. Various genetic modifications have been shown to play a role in the pathogenesis of this disease. Current treatment strategies span targeting epigenetic dysregulation, cell cycle, specific genetic alterations, and the immune microenvironment.

Summary

Herein, we review the complex features of this disease as it relates to current and past therapeutic approaches.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Data Availability

As a review, all data is provided in the manuscript.

References

  1. Di Ruscio V, Del Baldo G, Fabozzi F, Vinci M, Cacchione A, de Billy E, et al. Pediatric diffuse midline gliomas: an unfinished puzzle. Diagnostics (Basel). 2022;12(9):2064. https://doi.org/10.3390/diagnostics12092064.

  2. Buczkowicz P, Bartels U, Bouffet E, Becher O, Hawkins C. Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: diagnostic and therapeutic implications. Acta Neuropathol. 2014;128(4):573–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Cohen KJ, Jabado N, Grill J. Diffuse intrinsic pontine gliomas-current management and new biologic insights. Is there a glimmer of hope? Neuro Oncol. 2017;19(8):1025–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Karremann M, Gielen GH, Hoffmann M, Wiese M, Colditz N, Warmuth-Metz M, et al. Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location. Neuro Oncol. 2018;20(1):123–31.

    Article  CAS  PubMed  Google Scholar 

  5. Vitanza NA, Cho YJ. Advances in the biology and treatment of pediatric central nervous system tumors. Curr Opin Pediatr. 2016;28(1):34–9.

    Article  PubMed  Google Scholar 

  6. Caretti V, Bugiani M, Freret M, Schellen P, Jansen M, van Vuurden D, et al. Subventricular spread of diffuse intrinsic pontine glioma. Acta Neuropathol. 2014;128(4):605–7.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Benesch M, Wagner S, Berthold F, Wolff JE. Primary dissemination of high-grade gliomas in children: experiences from four studies of the Pediatric Oncology and Hematology Society of the German Language Group (GPOH). J Neurooncol. 2005;72(2):179–83.

    Article  PubMed  Google Scholar 

  8. Wagner S, Benesch M, Berthold F, Gnekow AK, Rutkowski S, Sträter R, et al. Secondary dissemination in children with high-grade malignant gliomas and diffuse intrinsic pontine gliomas. Br J Cancer. 2006;95(8):991–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Vallero SG, Bertero L, Morana G, Sciortino P, Bertin D, Mussano A, et al. Pediatric diffuse midline glioma H3K27- altered: a complex clinical and biological landscape behind a neatly defined tumor type. Front Oncol. 2022;12:1082062.

    Article  CAS  PubMed  Google Scholar 

  10. Mondal G, Lee JC, Ravindranathan A, Villanueva-Meyer JE, Tran QT, Allen SJ, et al. Pediatric bithalamic gliomas have a distinct epigenetic signature and frequent EGFR exon 20 insertions resulting in potential sensitivity to targeted kinase inhibition. Acta Neuropathol. 2020;139(6):1071–88.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Sievers P, Sill M, Schrimpf D, Stichel D, Reuss DE, Sturm D, et al. A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR. Neuro Oncol. 2021;23(1):34–43.

    Article  CAS  PubMed  Google Scholar 

  12. Buczkowicz P, Hawkins C. Pathology, molecular genetics, and epigenetics of diffuse intrinsic pontine glioma. Front Oncol. 2015;5:147.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Puget S, Philippe C, Bax DA, Job B, Varlet P, Junier MP, et al. Mesenchymal transition and PDGFRA amplification/mutation are key distinct oncogenic events in pediatric diffuse intrinsic pontine gliomas. PloS One. 2012;7(2):e30313.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Paugh BS, Broniscer A, Qu C, Miller CP, Zhang J, Tatevossian RG, et al. Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. J Clin Oncol. 2011;29(30):3999–4006.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Edwards M, Wara W, Urtasun R, Prados M, Levin V, Fulton D, et al. Hyperfractionated radiation therapy for brain-stem glioma: a phase I-II trial. J Neurosurg. 1989;70:691–700.

    Article  CAS  PubMed  Google Scholar 

  16. Freeman C, Krischer J, Sanford R, Cohen M, Burger P, Del Carpio R, et al. Final results of a study of escalating doses of hyperfractionated radiotherapy in brain stem tumors in children: a Pediatric Oncology Group study. Int J Radiat Oncol Biol Phys. 1993;27:197–206.

    Article  CAS  PubMed  Google Scholar 

  17. Packer R, Boyett J, Zimmerman R, Rorke L, Kaplan A, Albright A, et al. Hyperfractionated radiation therapy (72 Gy) for children with brain stem glioma: a Children’s Cancer Group Phase I/II Trial. Cancer. 1993;72:1414–21.

    Article  CAS  PubMed  Google Scholar 

  18. Veldhuijzen van Zanten SEM, El-Khouly FE, Jansen MHA, Bakker DP, Sanchez Aliaga E, Haasbeek CJA, et al. A phase I/II study of gemcitabine during radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma. J Neurooncol. 2017;135(2):307–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Carruthers R, Chalmers AJ. The potential of PARP inhibitors in neuro-oncology. CNS Oncol. 2012;1(1):85–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Chornenkyy Y, Agnihotri S, Yu M, Buczkowicz P, Rakopoulos P, Golbourn B, et al. Poly-ADP-ribose polymerase as a therapeutic target in pediatric diffuse intrinsic pontine glioma and pediatric high-grade astrocytoma. Mol Cancer Ther. 2015;14(11):2560–8.

    Article  CAS  PubMed  Google Scholar 

  21. Lesueur P, Chevalier F, Austry JB, Waissi W, Burckel H, Noël G, et al. Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies. Oncotarget. 2017;8(40):69105–24.

    Article  PubMed  PubMed Central  Google Scholar 

  22. van Vuurden DG, Hulleman E, Meijer OL, Wedekind LE, Kool M, Witt H, et al. PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation. Oncotarget. 2011;2(12):984–96.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Amsbaugh MJ, Mahajan A, Thall PF, McAleer MF, Paulino AC, Grosshans D, et al. A phase 1/2 trial of reirradiation for diffuse intrinsic pontine glioma. Int J Radiat Oncol Biol Phys. 2019;104(1):144–8.

    Article  PubMed  Google Scholar 

  24. Fontanilla HP, Pinnix CC, Ketonen LM, Woo SY, Vats TS, Rytting ME, et al. Palliative reirradiation for progressive diffuse intrinsic pontine glioma. Am J Clin Oncol. 2012;35(1):51–7.

    Article  PubMed  Google Scholar 

  25. Lassaletta A, Strother D, Laperriere N, Hukin J, Vanan MI, Goddard K, et al. Reirradiation in patients with diffuse intrinsic pontine gliomas: the Canadian experience. Pediatr Blood Cancer. 2018;65(6):e26988.

    Article  PubMed  Google Scholar 

  26. Cacciotti C, Liu KX, Haas-Kogan DA, Warren KE. Reirradiation practices for children with diffuse intrinsic pontine glioma. Neurooncol Pract. 2021;8(1):68–74.

    PubMed  Google Scholar 

  27. Fontanilla H, Pinnix C, Ketonen L, et al. Palliative reirradiation for progressive diffuse intrinsic pontine glioma. Am J Clin Oncol. 2012;35(1):51–7.

    Article  PubMed  Google Scholar 

  28. Massimino M, Biassoni V, Miceli R et al. Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhood. J Neurooncol. 2014;118(2):305–12.

    CAS  PubMed  Google Scholar 

  29. Janssens G, Gandola L, Bolle S et al. Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: a matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working group. Eur J Cancer. 2017;73:38–47.

    Article  PubMed  Google Scholar 

  30. Amsbaugh M, Mahajan A, Thall P et al. A phase 1/2 trial of reirradiation for diffuse intrinsic pontine glioma. Int J Radiat Oncol Biol Phys. 2019;104(1):144–8.

    Article  PubMed  Google Scholar 

  31. Rodriguez D, Calmon R, Aliaga ES, Warren D, Warmuth-Metz M, Jones C, et al. MRI and molecular characterization of pediatric high-grade midline thalamic gliomas: the HERBY Phase II Trial. Radiology. 2022;304(1):174–82.

    Article  PubMed  Google Scholar 

  32. Jansen MH, van Vuurden DG, Vandertop WP, Kaspers GJ. Diffuse intrinsic pontine gliomas: a systematic update on clinical trials and biology. Cancer Treat Rev. 2012;38(1):27–35.

    Article  CAS  PubMed  Google Scholar 

  33. Sanghavi SN, Needle MN, Krailo MD, Geyer JR, Ater J, Mehta MP. A phase I study of topotecan as a radiosensitizer for brainstem glioma of childhood: first report of the Children’s Cancer Group-0952. Neuro Oncol. 2003;5(1):8–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Cohen KJ, Heideman RL, Zhou T, Holmes EJ, Lavey RS, Bouffet E, et al. Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group. Neuro Oncol. 2011;13(4):410–6.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Wagner S, Reinert C, Schmid HJ, Liebeskind AK, Jorch N, Längler A, et al. High-dose methotrexate prior to simultaneous radiochemotherapy in children with malignant high-grade gliomas. Anticancer Res. 2005;25(3c):2583–7.

    CAS  PubMed  Google Scholar 

  36. Itazaki H, Nagashima K, Sugita K, Yoshida H, Kawamura Y, Yasuda Y, et al. Isolation and structural elucidation of new cyclotetrapeptides, trapoxins A and B, having detransformation activities as antitumor agents. J Antibiot (Tokyo). 1990;43(12):1524–32.

    Article  CAS  PubMed  Google Scholar 

  37. Sugita K, Koizumi K, Yoshida H. Morphological reversion of sis-transformed NIH3T3 cells by trichostatin A. Cancer Res. 1992;52(1):168–72.

    CAS  PubMed  Google Scholar 

  38. Medina V, Edmonds B, Young G, James R, Appleton S, Zalewski P. Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway. Cancer Res. 1997;57(17):3697–707.

    CAS  PubMed  Google Scholar 

  39. Leszczynska KB, Jayaprakash C, Kaminska B, Mieczkowski J. Emerging advances in combinatorial treatments of epigenetically altered pediatric high-grade H3K27M gliomas. Front Genet. 2021;12:742561.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Hennika T, Hu G, Olaciregui NG, Barton KL, Ehteda A, Chitranjan A, et al. Pre-clinical study of panobinostat in xenograft and genetically engineered murine diffuse intrinsic pontine glioma models. PloS One. 2017;12(1):e0169485.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Wang ZJ, Ge Y, Altinok D, Poulik J, Sood S, Taub JW, et al. Concomitant use of panobinostat and reirradiation in progressive DIPG: report of 2 cases. J Pediatr Hematol Oncol. 2017;39(6):e332–e5.

    Article  PubMed  Google Scholar 

  42. Su JM, Kilburn LB, Mansur DB, Krailo M, Buxton A, Adekunle A, et al. Phase I/II trial of vorinostat and radiation and maintenance vorinostat in children with diffuse intrinsic pontine glioma: a Children’s Oncology Group report. Neuro Oncol. 2022;24(4):655–64.

    Article  CAS  PubMed  Google Scholar 

  43. Truffaux N, Philippe C, Paulsson J, Andreiuolo F, Guerrini-Rousseau L, Cornilleau G, et al. Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma. Neuro Oncol. 2015;17(7):953–64.

    Article  CAS  PubMed  Google Scholar 

  44. Pollack IF, Jakacki RI, Blaney SM, Hancock ML, Kieran MW, Phillips P, et al. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neuro Oncol. 2007;9(2):145–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Broniscer A, Baker SD, Wetmore C, Pai Panandiker AS, Huang J, Davidoff AM, et al. Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma. Clin Cancer Res. 2013;19(11):3050–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Broniscer A, Baker JN, Tagen M, Onar-Thomas A, Gilbertson RJ, Davidoff AM, et al. Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma. J Clin Oncol. 2010;28(31):4762–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Carvalho DM, Richardson PJ, Olaciregui N, Stankunaite R, Lavarino C, Molinari V, et al. Repurposing vandetanib plus everolimus for the treatment of. Cancer Discov. 2022;12(2):416–31.

    Article  CAS  PubMed  Google Scholar 

  48. Geyer JR, Stewart CF, Kocak M, Broniscer A, Phillips P, Douglas JG, et al. A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas. Eur J Cancer. 2010;46(18):3287–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Geoerger B, Hargrave D, Thomas F, Ndiaye A, Frappaz D, Andreiuolo F, et al. Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. Neuro Oncol. 2011;13(1):109–18.

    Article  CAS  PubMed  Google Scholar 

  50. Grill J, Le Teuff G, Nysom K, Blomgren K, Hargrave D, McCowage G, et al. PDCT-01. Biological medicine for diffuse intrinsic pontine gliomas eradication (Biomede): results of the three-arm biomarker-driveN randomized trial in the first 230 patients from Europe and Australia. Neuro Oncol. 2019;21:vi183. © The Author(s) 2019. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com

    Article  PubMed Central  Google Scholar 

  51. Persson ML, Douglas AM, Alvaro F, Faridi P, Larsen MR, Alonso MM, et al. The intrinsic and microenvironmental features of diffuse midline glioma: implications for the development of effective immunotherapeutic treatment strategies. Neuro Oncol. 2022;24(9):1408–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Becher OJ, Millard NE, Modak S, Kushner BH, Haque S, Spasojevic I, et al. A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors. PloS One. 2017;12(6):e0178593.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Becher OJ, Gilheeney SW, Khakoo Y, Lyden DC, Haque S, De Braganca KC, et al. A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors. Pediatr Blood Cancer. 2017;64(7). https://doi.org/10.1002/pbc.26409.

  54. Erker C, Lane A, Chaney B, Leary S, Minturn JE, Bartels U, et al. Characteristics of patients ≥10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry. Neuro Oncol. 2022;24(1):141–52.

    Article  CAS  PubMed  Google Scholar 

  55. Vanan MI, Eisenstat DD. DIPG in children - what can we learn from the past? Front Oncol. 2015;5:237.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Massimino M, Biassoni V, Miceli R, Schiavello E, Warmuth-Metz M, Modena P, et al. Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhood. J Neurooncol. 2014;118(2):305–12.

    CAS  PubMed  Google Scholar 

  57. Fleischhack G, Massimino M, Warmuth-Metz M, Khuhlaeva E, Janssen G, Graf N, et al. Nimotuzumab and radiotherapy for treatment of newly diagnosed diffuse intrinsic pontine glioma (DIPG): a phase III clinical study. J Neurooncol. 2019;143(1):107–13.

    Article  CAS  PubMed  Google Scholar 

  58. Kebudi R, Cakir FB, Bay SB, Gorgun O, Altınok P, Iribas A, et al. Nimotuzumab-containing regimen for pediatric diffuse intrinsic pontine gliomas: a retrospective multicenter study and review of the literature. Childs Nerv Syst. 2019;35(1):83–9.

    Article  PubMed  Google Scholar 

  59. Parenrengi MA, Suryaningtyas W, Al Fauzi A, Hafid Bajamal A, Kusumastuti K, Utomo B, et al. Nimotuzumab as additional therapy for GLIOMA in pediatric and adolescent: a systematic review. Cancer Control. 2022;29:10732748211053927.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Matthews HK, Bertoli C, de Bruin RAM. Cell cycle control in cancer. Nat Rev Mol Cell Biol. 2022;23(1):74–88.

    Article  CAS  PubMed  Google Scholar 

  61. DeWire M, Fuller C, Hummel TR, Chow LML, Salloum R, de Blank P, et al. A phase I/II study of ribociclib following radiation therapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG). J Neurooncol. 2020;149(3):511–22.

    Article  CAS  PubMed  Google Scholar 

  62. Schüller U, Iglauer P, Dorostkar MM, Mawrin C, Herms J, Giese A, et al. Mutations within FGFR1 are associated with superior outcome in a series of 83 diffuse midline gliomas with H3F3A K27M mutations. Acta Neuropathol. 2021;141(2):323–5.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Nguyen AT, Colin C, Nanni-Metellus I, Padovani L, Maurage CA, Varlet P, et al. Evidence for BRAF V600E and H3F3A K27M double mutations in paediatric glial and glioneuronal tumours. Neuropathol Appl Neurobiol. 2015;41(3):403–8.

    Article  CAS  PubMed  Google Scholar 

  64. Solomon DA, Wood MD, Tihan T, Bollen AW, Gupta N, Phillips JJ, et al. Diffuse midline gliomas with histone H3-K27M mutation: a series of 47 cases assessing the spectrum of morphologic variation and associated genetic alterations. Brain Pathol. 2016;26(5):569–80.

    Article  CAS  PubMed  Google Scholar 

  65. Joyon N, Tauziède-Espariat A, Alentorn A, Giry M, Castel D, Capelle L, et al. K27M mutation in H3F3A in ganglioglioma grade I with spontaneous malignant transformation extends the histopathological spectrum of the histone H3 oncogenic pathway. Neuropathol Appl Neurobiol. 2017;43(3):271–6.

    Article  CAS  PubMed  Google Scholar 

  66. Pagès M, Beccaria K, Boddaert N, Saffroy R, Besnard A, Castel D, et al. Co-occurrence of histone H3 K27M and BRAF V600E mutations in paediatric midline grade I ganglioglioma. Brain Pathol. 2018;28(1):103–11.

    Article  PubMed  Google Scholar 

  67. Ryall S, Zapotocky M, Fukuoka K, Nobre L, Guerreiro Stucklin A, Bennett J, et al. Integrated molecular and clinical analysis of 1,000 pediatric low-grade gliomas. Cancer Cell. 2020;37(4):569–83.e5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Blumenthal DT, Yalon M, Vainer GW, Lossos A, Yust S, Tzach L, et al. Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors. J Neurooncol. 2016;129(3):453–60.

    Article  CAS  PubMed  Google Scholar 

  69. Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 2019;25(3):477–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Johnson DB, Sullivan RJ, Menzies AM. Immune checkpoint inhibitors in challenging populations. Cancer. 2017;123(11):1904–11.

    Article  PubMed  Google Scholar 

  72. Cacciotti C, Choi J, Alexandrescu S, Zimmerman MA, Cooney TM, Chordas C, et al. Immune checkpoint inhibition for pediatric patients with recurrent/refractory CNS tumors: a single institution experience. J Neurooncol. 2020;149(1):113–22.

    Article  CAS  PubMed  Google Scholar 

  73. Kline C, Liu SJ, Duriseti S, Banerjee A, Nicolaides T, Raber S, et al. Reirradiation and PD-1 inhibition with nivolumab for the treatment of recurrent diffuse intrinsic pontine glioma: a single-institution experience. J Neurooncol. 2018;140(3):629–38.

    Article  CAS  PubMed  Google Scholar 

  74. Hwang E, Onar A, Young-Poussaint T, Mitchell D, Kilburn L, Margol A, et al. IMMU-09.Outcome of patients with recurrent diffuse intrinsic pontine glioma (DIPG) treated with pembrolizumab (anti-PD-1): a pediatric brain tumor consortium study (PBTC045). Neuro Oncol. 2018;20(Suppl 2):i100.

    Article  PubMed Central  Google Scholar 

  75. Ochs K, Ott M, Bunse T, Sahm F, Bunse L, Deumelandt K, et al. K27M-mutant histone-3 as a novel target for glioma immunotherapy. Oncoimmunology. 2017;6(7):e1328340.

    Article  PubMed  PubMed Central  Google Scholar 

  76. Vandenberk L, Belmans J, Van Woensel M, Riva M, Van Gool SW. Exploiting the immunogenic potential of cancer cells for improved dendritic cell vaccines. Front Immunol. 2015;6:663.

    PubMed  Google Scholar 

  77. Benitez-Ribas D, Cabezón R, Flórez-Grau G, Molero MC, Puerta P, Guillen A, et al. Immune response generated with the administration of autologous dendritic cells pulsed with an allogenic tumoral cell-lines lysate in patients with newly diagnosed diffuse intrinsic pontine glioma. Front Oncol. 2018;8:127.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Martínez-Vélez N, Garcia-Moure M, Marigil M, González-Huarriz M, Puigdelloses M, Gallego Pérez-Larraya J, et al. The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models. Nat Commun. 2019;10(1):2235.

    Article  PubMed  PubMed Central  Google Scholar 

  79. de Billy E, Pellegrino M, Orlando D, Pericoli G, Ferretti R, Businaro P, et al. Dual IGF1R/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutant. Neuro Oncol. 2022;24(7):1150–63.

    Article  PubMed  Google Scholar 

  80. Majzner RG, Ramakrishna S, Yeom KW, Patel S, Chinnasamy H, Schultz LM, et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature. 2022;603(7903):934–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Mount CW, Majzner R, Sundaresh S, Arnold EP, Kadapakkam M, Haile S, et al. Abstract 958: Anti-GD2 chimeric antigen receptor T cells as a potent immunotherapy regimen in xenograft models of histone 3 K27M mutant diffuse midline glioma. Cancer Res. 2018;78(13 Supplement):958.

    Article  Google Scholar 

  82. Mount CW, Majzner RG, Sundaresh S, Arnold EP, Kadapakkam M, Haile S, et al. Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas. Nat Med. 2018;24(5):572.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Children’s Hospital London Health Sciences/Western University, London, ON, Canada

    Chantel Cacciotti

  2. Dana Farber/Boston Children’s Cancer and Blood Disorder Center, Boston, MA, USA

    Karen D. Wright

Authors
  1. Chantel Cacciotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karen D. Wright
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors equally contributed to this manuscript. C.C. and K.W wrote the manuscript. The table was created by C.C. The manuscript was reviewed and edited by C.C and K.W. All authors approved the final version of the manuscript prior to submission.

Corresponding author

Correspondence to Chantel Cacciotti.

Ethics declarations

Ethics Approval

Not applicable, as this was a review.

Conflict of Interest

The authors declare no competing interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cacciotti, C., Wright, K.D. Advances in Treatment of Diffuse Midline Gliomas. Curr Neurol Neurosci Rep 23, 849–856 (2023). https://doi.org/10.1007/s11910-023-01317-8

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11910-023-01317-8

Keywords

Search

Navigation